The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 28, 2019

Filed:

Sep. 17, 2014
Applicants:

Institut Pasteur, Paris, FR;

Centre National DE LA Recherche Scientifique, Paris, FR;

Universite Paris Diderot—paris 7, Paris, FR;

Inventors:

Monica Sala, Paris, FR;

Daria Jacob, Paris, FR;

Frederic Tangy, Les Lilas, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/165 (2006.01); C12N 7/00 (2006.01); A61K 39/015 (2006.01); A61K 39/125 (2006.01); C07K 14/005 (2006.01); C07K 14/445 (2006.01); C12N 15/81 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/165 (2013.01); A61K 39/015 (2013.01); A61K 39/125 (2013.01); C07K 14/005 (2013.01); C07K 14/445 (2013.01); C12N 7/00 (2013.01); C12N 15/815 (2013.01); A61K 2039/521 (2013.01); A61K 2039/523 (2013.01); A61K 2039/542 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/70 (2013.01); C07K 2319/85 (2013.01); C12N 2760/18422 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18451 (2013.01); C12N 2760/18471 (2013.01); C12N 2770/32322 (2013.01); C12N 2770/32334 (2013.01); C12N 2770/32351 (2013.01); Y02A 50/412 (2018.01);
Abstract

The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) comprising nucleoproteins of a non-segmented negative-strand ribonucleic acid (RNA) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric RNPs resulting from the assembly of at least 200 fusion proteins with a cellular RNA, or to recombinant yeasts or yeast lysates expressing these multimeric RNPs. It also concerns a process for the preparation of these multimeric RNPs or recombinant yeasts or yeast lysates. In particular, the present invention relates to their use as active ingredient for the in vitro production of an immunogenic composition or in eliciting a protective prophylactic or a therapeutic immune response against said heterologous polypeptide in a host in need thereof. Recombinant yeasts or yeast lysates of the invention can also be used as expression and vector systems for delivery to a host.


Find Patent Forward Citations

Loading…